Video Experimental Relacionado
Updated: Aug 15, 2026
08:47
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
Hipoglucemia debido a un anticuerpo receptor de insulina en la enfermedad de Hodgkin
Lancet (London, England)
|January 31, 1987
Resumen
Un paciente con enfermedad de Hodgkin desarrolló hipoglucemia severa debido a un anticuerpo del receptor de insulina. Este autoanticuerpo imitaba los efectos de la insulina, causando peligrosas caídas en el azúcar en la sangre.
Área de la Ciencia:
- Endocrinología Endocrinología.
- En oncoinmunología.
- Trastornos metabólicos Los trastornos metabólicos incluyen trastornos metabólicos.
Sus antecedentes:
- La quimioterapia para la enfermedad de Hodgkin puede tener efectos secundarios metabólicos complejos.
- La hipoglucemia en ayunas es una complicación rara pero grave que justifica una investigación.
Objetivo del estudio:
- Para investigar la causa de la hipoglucemia severa en ayunas en un paciente con enfermedad de Hodgkin.
- Para identificar la naturaleza del factor en el suero del paciente responsable de la hipoglucemia.
- Explorar el mecanismo de acción de este factor en el metabolismo de la glucosa.
Principales métodos:
- Análisis de la absorción de glucosa en los adipocitos de rata.
- Aislamiento de la fracción de inmunoglobulina sérica.
- Investigación de la unión de la insulina a los eritrocitos humanos.
- Análisis de la precipitación y fosforilación de los receptores de insulina utilizando extractos de placenta humana.
Principales resultados:
- El suero del paciente contenía un factor que estimulaba la captación de glucosa en los adipocitos.
- Este factor se localizó en la fracción de inmunoglobulina.
- El factor sérico desplazó a la insulina unida e interactuó con los receptores de insulina.
- La evidencia sugería que el factor era un autoanticuerpo contra el receptor de insulina.
Conclusiones:
- La hipoglucemia del paciente fue causada por un autoanticuerpo dirigido al receptor de insulina.
- Este autoanticuerpo exhibe actividad similar a la insulina.
- Este caso destaca una rara complicación paraneoplásica o autoinmune relacionada con el tratamiento en la enfermedad de Hodgkin.
Videos de Conceptos Relacionados
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...